Home/Pipeline/Band-assisted Duodenal Mucosal Resurfacing (DMR)

Band-assisted Duodenal Mucosal Resurfacing (DMR)

Type 2 Diabetes

Pre-clinicalActive

Key Facts

Indication

Type 2 Diabetes

Phase

Pre-clinical

Status

Active

Company

Endolastic

About Endolastic

Endolastic is a private, pre-revenue medical device company advancing its EndoBand™ platform for endoscopic, band-based interventions. With over 50 successful human cases using its first-generation device, the company is preparing for commercial launch and regulatory filings, supported by a $4M physician-led seed round. Its technology aims to offer a durable, anatomical solution for GERD, obesity, and diabetes, positioned between pharmaceutical therapies and invasive surgery in terms of efficacy, cost, and procedural simplicity.

View full company profile

Therapeutic Areas

Gastroesophageal Reflux Disease (GERD)Obesity Type 2 Diabetes

Other Type 2 Diabetes Drugs

Drug	Company	Phase	Status
Diabetes Management Gel	Gelteq Limited	Formulation Development	Active
Tolimidone	Biodexa Pharmaceuticals	Phase 2	Acquired Asset
Generic Semaglutide Injection (Obeda)	Dr. Reddy's Laboratories	Approved	Launched in India
BioChaperone® Lispro	Adocia	Phase 3	Active
BioChaperone® Combo (Insulin Glargine / Lixisenatide)	Adocia	Phase 2	Active
Metformin API	USV Biologics Division	Commercial	Active
Empagliflozin	Azico Biophore	Commercial	Active
Sitagliptin Intermediate	AR Life Science	Commercial	Active
AJN003 (LuCI™)	AltrixBio	Pre-clinical	Advancing to Phase 1 (planned 2026)
Sitagliptin Phosphate Polymorph	Morepen Laboratories	Pre‑clinical	Active
Hepatic Denervation for Type 2 Diabetes	Metavention	Feasibility	Active
MVD-1 (SANA)	Eolo Pharma	Discovery	Active